Pharmacoeconomic Analysis of Price Variability in Topical Tofacitinib and Crisaborole Across Different Brands in India: Implications for Accessibility and Regulatory Policy
DOI:
https://doi.org/10.52783/jns.v14.3276Keywords:
Azilsartan Medoxomil, Solid dispersion, Solubility enhancement, Pharmacokinetic, BioavailabilityAbstract
Background: The Indian pharmaceutical sector is characterized by notable price disparities across different brands of identical drug formulations and strengths. This variation poses substantial challenges for affordability, especially given the limited scope of medical insurance coverage in India, which escalates out-of-pocket healthcare costs. Our study aimed to evaluate the pricing disparities of topical Tofacitinib and Crisaborole and assess their potential effects on the accessibility and affordability of these treatments.
Methodology: We conducted an analysis on seven Tofacitinib and seventeen Crisaborole formulations available in the Indian market. Data on pricing were collected from the 1mg online platform from January to April 2024. The analysis included calculating the cost range, mean cost, cost ratio, and percentage price variation for each drug strength. The study focused exclusively on standalone topical formulations represented by multiple brands, excluding single-manufacturer generics and fixed-dose combinations.
Results: Our findings reveal that Tofacitinib 20 g strength displayed the most significant price variation at 11%, while the 15 g strength exhibited the least variation at 6%. For Crisaborole, the 30 g strength had the most substantial price fluctuation at 262%, whereas the 10 g strength had the lowest at 50%. The diversity in the number of brands per drug strength ranged from 2 to 17, indicating differing levels of market competition.
Conclusion: The study underscores critical price disparities in topical Tofacitinib and Crisaborole formulations that could hinder patient adherence and economic accessibility. To mitigate these disparities, pharmacoeconomic research and regulatory interventions are imperative. These should include strategies for enhanced regulatory oversight and the implementation of transparent pricing mechanisms, thereby ensuring equitable access to vital medications without compromising their therapeutic efficacy.
Downloads
Metrics
References
Callender, V. D., Jackson, J. M., & Zirwas, M. J. (2020). Crisaborole 2% ointment provides sustained improvement in disease severity and pruritus: A pooled post hoc analysis of two pivotal trials. Indian Journal of Drugs in Dermatology, 7(1), 9-16. Retrieved from http://www.ijdd.in
Stein Gold, L., Paller, A. S., & Tom, W. L. (2024). Comparing the efficacy and safety of roflumilast and crisaborole in atopic dermatitis. Dermatology Times. Retrieved from https://www.dermatologytimes.com/
Paller, A. S., Mancini, A. J., & Eichenfield, L. F. (2021). Practical considerations and patient care with crisaborole in atopic dermatitis: Outcomes from a panel discussion. Journal of the American Academy of Dermatology. Retrieved from https://www.jaad.org/
Gupta, M., & Thakur, V. (2022). Efficacy of crisaborole in a real-world setting: Observational data across different ethnic groups. Indian Dermatology Online Journal, 12, 45-52. Retrieved from http://www.idoj.in
Samdani, G. B. (2021). The pharmacoeconomics of atopic dermatitis treatments in India: Focus on crisaborole and tofacitinib. Indian Journal of Clinical Dermatology, 4, 112-119.
Kaur, I., & Handa, S. (2023). Price analysis of tofacitinib and crisaborole in managing atopic dermatitis: A market survey in northern India. Journal of Dermatological Treatment. Retrieved from https://www.tandfonline.com/
Kumar, P., & Agarwal, R. (2024). Review of cost-effectiveness and market competition among novel nonsteroidal topical treatments in dermatology. Indian Journal of Health Economics and Policy Analysis, 2(1), 33-41.
Patel, S. S., & Singh, H. P. (2024). Regulatory perspectives on price variability of topical treatments for dermatological conditions in India. Indian Journal of Pharmaceutical Sciences, 86(4), 460-468.
Chawla, Y., Badwaik, G., & Ganad, D. (2016). Analysis of price variation amongst different formulations of antipsychotic drugs available in Indian market. Indian Journal of Pharmacy and Medical Sciences, 20(3), 280–284. Available from: https://doi.org/10.32476/IJPMS.2016.3.280-284
Das, S. C., Mandal, M., & Sarraf, A. (2006). A critical study on availability and price variation between different brands: Impact on access to medicines. Indian Pharmacist, 5(50), 207-189.
Mehani, R., & Sharma, R. (2013). Cost variation analysis of oral antidiabetic drugs. Journal of Basic Clinical Pharmacy, 2013(4), 79-103.
Mir, S. A. (2016). Cost variation analysis of different brands of commonly prescribed antihypertensive drugs, available in Indian market. Pharmacoeconomics, 6(1), 28-34. Available from: https://doi.org/10.7454/phar.econ.2016.28-34
Kalaria, S., & Dhrohar, A. (2015). Pharmacoeconomic analysis of drugs used for peptic ulcer in India. Indian Journal of Basic Clinical Pharmacology, 2015(12), 57-62. Available from: https://doi.org/10.18329/2310-2093-2015-jbcp.205540
& 7. UDAYL Textbook of Dermatology, 5th edition, volumes 1-2, pp. 420-505.
(No author listed). (2014). Current Burden of Atopic Dermatitis in India: A Systematic Literature Review. Current Reports of Atopic Dermatitis in India: A Systematic Literature Review [Journal]. Available from: https://doi.org/10.1016/j.crad.2014.10.018
Lung, D. W. (2013). New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergology International, 2013(62), 151-160. Available from: https://doi.org/10.2332/allergolint.13-RA-0544
Williams, H. C. (2012). Atopic Dermatitis: The epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press.
Harvey, L., Law, S., Asten, A., Lavett, R., Lawton, S., Lang, S., et al. (2013). The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review. British Journal of Dermatology, 2013(20), 328-337. Available from: https://doi.org/10.1017/S1234567890000012
Debora, A.H., & Jason, H. (2016). Cost-Effectiveness of Natural Health Products: A systematic review of randomized clinical trials.
Tolia, N. (2008). Canadian Self-care Industry Profile of Non-prescription Drug, Manufacturers Association of Canada, Canada, 2008-2013.
Ray, M. (1991). Pharma-Economics Manual: A Beginning Text Book of Pharmaceutical Science and Practice of Pharmacy. Boston Economics Press, Mumbai Publication, 1991.
& 16. McMan, W. (1991). Pharma-Economics Manual: A Beginning Text Book of Pharmaceutical Science and Practice of Pharmacy. Boston Economics Press, Mumbai Publication, 1991.
Srinivasar, S., Shukla, V., & Udapi, A. O. (2006). Implementation of principles of pharmacoeconomics and pharmacology to achieve optimal formulary and public health policy with WHO. Essential Medicine Policy and Publication-National Hospital Management [Journal], Times Med Journal, 2010(18), 92-97. Available from: https://doi.org/10.4103/1000-jfmpe.2010_297
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
